Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [11] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Mei, Matthew
    Salhotra, Amandeep
    Khaled, Samer
    Nakamura, Ryotaro
    Snyder, David
    O'Donnell, Margaret
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
  • [12] Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent
    On, Sandy
    Rath, Carolyn G.
    Lan, Michelle
    Wu, Bobby
    Lau, Kimberly M.
    Cheung, Edna
    Alegria, William
    Young, Rebecca
    Tan, Marisela
    Kim, Carrie
    Phun, Jennifer
    Patel, Nimish
    Mannis, Gabriel
    Logan, Aaron C.
    Kennedy, Vanessa
    Goodman, Aaron
    Taplitz, Randy A.
    Young, Patricia A.
    Wen, Raymond
    Saunders, Ila M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (01) : 63 - 70
  • [13] Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
    Juliusson, Gunnar
    LANCET HAEMATOLOGY, 2022, 9 (05): : E317 - E318
  • [14] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [15] Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
    Matthews, Andrew H.
    Perl, Alexander E.
    Luger, Selina M.
    Gill, Saar I.
    Lai, Catherine
    Porter, David L.
    Skuli, Sarah
    Bruno, Ximena Jordan
    Carroll, Martin P.
    Freyer, Craig W.
    Carulli, Alison
    Babushok, Daria V.
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Stadtmauer, Edward A.
    Loren, Alison W.
    Paralkar, Vikram R.
    Maillard, Ivan P.
    Pratz, Keith W.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (08) : 1254 - 1264
  • [16] Comparison of Salvage Intensive Chemotherapy Versus Venetoclax Combined Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Park, Silvia
    Kim, Hee-Je
    Cho, Byung Sik
    Kim, Yoo-Jin
    Min, Gi June
    Park, Sung-Soo
    Yahng, Seung-Ah
    Jeon, Young-Woo
    Shin, Seung-Hwan
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    BLOOD, 2021, 138
  • [17] Treatment of relapsed/refractory acute myeloid leukaemia in adults
    Rashidi, Armin
    Weisdorf, Daniel J.
    Bejanyan, Nelli
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 27 - 37
  • [18] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [19] PRELIMINARY TREATMENT EXPERIENCE OF ACUTE MYELOID LEUKAEMIA WITH VENETOCLAX IN ASSOCIATION WITH FIRST-LINE HYPOMETHYLATING AGENTS OR RELAPSED/REFRACTORY DISEASE
    Jimenez, Vicente C.
    Bataller, A.
    Castano, Diez S.
    Guijarro, F.
    Esteban, D.
    Gomez, Hernando M.
    Castillo, Giron C. M.
    Charry, P.
    Palomino, A.
    Garrote, M.
    Rivero, A.
    Moreno, D. F.
    Martinez, Roca A. P.
    Alvarez, Larran A.
    Socoro, Yuste N.
    Riu, G.
    Monge, I
    Carcelero, E.
    Diaz, Beya M.
    Esteve, J.
    HAEMATOLOGICA, 2020, 105 : 47 - 48
  • [20] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
12345